21:31 , May 28, 2019 |  BC Extra  |  Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

A licensing deal with Lilly for an analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion will receive $47.5 million up front and is eligible for $950 million...
19:57 , Apr 12, 2019 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
18:43 , Dec 5, 2018 |  BC Extra  |  Politics & Policy

FDA NASH guidance charts course for surrogate endpoints tied to biopsies

Four companies with products in Phase III testing to treat non-alcoholic steatohepatitis are well positioned to meet endpoints that could support accelerated approval, according to requirements outlined in new FDA draft guidance. However, the guidance...
19:20 , Nov 19, 2018 |  BC Extra  |  Financial News

NASH company Genfit planning U.S. listing

As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic steatohepatitis, French bellwether Genfit S.A. (Euronext:GNFT) intends to conduct a listing on a U.S. exchange. Genfit said...
18:49 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
20:30 , Oct 29, 2018 |  BC Extra  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
19:32 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...